The Reducing Adverse Outcomes in Dialysis by Adjusting the pRescription for Dialysate Potassium Trial

Launched by NYU LANGONE HEALTH · Jun 26, 2025

Keywords

ClinConnect Summary

This clinical trial is studying a new way to manage potassium levels during dialysis for people with end-stage kidney disease, a serious condition where the kidneys no longer work well enough to keep the body healthy. The study will compare the usual method of prescribing potassium in the dialysis fluid to a more personalized approach. In this new approach, blood potassium levels will be tested right before each dialysis session, and the potassium in the dialysis fluid will be adjusted based on those results. The goal is to reduce harmful side effects that can happen when potassium levels are too high or too low during treatment.

People who might be eligible for this study are adults aged 21 or older who have been receiving regular in-center dialysis three times a week for at least three months. Participants should be prescribed up to 15 hours of dialysis per week. Some people, like those who are pregnant, have very low blood counts, or have a very high potassium level recently, won’t be able to join. If you join, you can expect regular blood tests before dialysis sessions, and your treatment may be adjusted to better match your individual needs. This study is not yet recruiting, but it aims to find safer and more effective ways to help people on dialysis stay healthier.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Undergoing in-center, 3x/weekly HD for treatment of end-stage kidney disease (ESKD) for at least 90 days
• • Age at least 21 years
• • Prescribed HD time up to 15 hours/ week
• Exclusion Criteria:
• • Incarcerated
• • Life expectancy of 1 year or less
• • Kidney transplant, transition to home dialysis, or transfer to non-participating HD unit anticipated within 6 months or less
• • Cognitive condition that precludes consent
• • Severe anemia (hemoglobin \< 8.0 g/dL) within 30 days
• • K concentration of 7.0 mEq/L or more within 60 days
• • Pregnant women
• • Women of childbearing potential actively trying to conceive unwilling to use contraception
• • Participation in other interventional studies within 30 days prior to enrollment